Intervention

Mitoxantrone Hydrochloride Liposome Injection

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

3 shown

A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisNCT05496894 · 2022-08-01

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerNCT04927481 · 2021-06-11

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast CancerNCT02596373 · 2015-06-01

Common conditions

Advanced Recurrent or Metastatic Breast Cancer1 Breast Cancer1 Relapsing Multiple Sclerosis1

Leading sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1

Trial status mix

TERMINATED1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.